Lupin's Ankleshwar Facility Receives Establishment Inspection Report (EIR) from U.S. FDA
Global pharmaceutical major Lupin Limited announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar facility in Gujarat, India. The report followed the closure of a productspecific Pre-Approval Inspection conducted between March 2 and March 7, 2026.Nilesh Gupta, Managing Director of Lupin, stated that the receipt of the EIR is a significant outcome. He noted that the achievement reflects the company's ongoing commitment to quality excellence and regulatory compliance, reinforcing Lupin's dedication to delivering safe and effective medicines globally.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India. The company distributes its products in over 100 markets, specializing in a range of pharmaceutical products. Lupin's portfolio includes branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.
The organization holds a strong position in India and the U.S. across multiple therapeutic areas, including anti-infective, gastrointestinal, respiratory, cardiovascular, central nervous system, and women's health. Lupin operates 15 state-of-the-art manufacturing sites and 7 research centers across the globe, supported by a workforce exceeding 24,000 professionals. Through its subsidiaries, Lupin is committed to improving patient health outcomes via Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
LUPIN Stock Price Movement
On Wednesday, Lupin Limited shares climbed, posting a gain of 0.40% to close at ₹2276.4. The stock saw 568,728 shares traded during the session, signaling buying interest across the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.